Generalized Anxiety Disorder (GAD) — Treatment

Overview

First-Line Pharmacotherapy: SSRIs and SNRIs

• Start at approximately half the usual antidepressant dose — patients with anxiety are more sensitive to side effects and may experience paradoxical worsening at high initial doses
• Titrate slowly
• Onset of anxiolytic benefit: 2–6 weeks
• Citalopram and fluoxetine have no large RCT evidence for GAD specifically but are used on the assumption of SSRI class effect

Second-Line Pharmacotherapy

Benzodiazepines

Buspirone

• Azapirone; 5-HT₁A partial agonist
• FDA-approved for GAD
• Requires chronic administration (2–4 weeks) to work — like SSRIs
• Lacks sedation and abuse potential of benzodiazepines
• Best in benzodiazepine-naive patients; less effective in those previously exposed to benzodiazepines
• Used as monotherapy in mild–moderate GAD or as an augmenting agent to SSRIs/SNRIs

Pregabalin (α₂δ Ligand)

• Approved for GAD in Europe and many other countries (not FDA-approved for anxiety in the US — used off-label)
• Meta-analysis found pregabalin has the largest effect size (0.50) among all pharmacological agents tested for GAD, including SSRIs, SNRIs, benzodiazepines, and buspirone
• Effective for relapse prevention over 6 months
• Designated Schedule V controlled substance in the US
• Also treats comorbid insomnia in GAD patients
• Gabapentin is used similarly off-label

Hydroxyzine

• Antihistamine; FDA-approved for anxiety/GAD
• Meta-analysis effect size of 0.45 (larger than SSRIs at 0.36)
• Sedating; lacks efficacy in comorbid disorders — reserved for patients without significant comorbidities
• Second-line; alternative to benzodiazepines when comorbid depression is absent

Quetiapine (Atypical Antipsychotic)

• Second-line option in treatment-resistant or difficult-to-treat GAD
• Supported by RCT evidence
• Limited by metabolic side effects

Other Second-Line / Off-Label Agents

• TCAs (imipramine has strongest GAD evidence) — effective but relegated to second-line due to anticholinergic effects, orthostatic hypotension, and lethality in overdose
• Agomelatine — melatonin receptor agonist/5-HT₂C antagonist; a recent network meta-analysis (PMID 38804215) supports its efficacy in GAD
• Mirtazapine, trazodone, vilazodone — off-label options; mirtazapine shows promise in open-label trials
• Hydroxyzine — antihistamine; FDA-approved, useful in mild GAD without comorbidities
• MAOIs — effective but rarely used due to dietary tyramine restrictions and drug interactions; reserved for treatment-resistant cases in psychiatric settings
• Beta-blockers (propranolol, pindolol) — block somatic symptoms of anxiety (tachycardia, sweating) but ineffective against cognitive/psychic symptoms of GAD such as worry

Psychotherapy

• Addresses cognitive distortions and avoidance behaviors
• Efficacy comparable to pharmacotherapy in head-to-head trials
• Combined CBT + pharmacotherapy is generally more effective than either alone
• Includes relaxation training, worry exposure, behavioral experiments
• A 2025 Bayesian network meta-analysis (PMID 40367584) confirms that third-wave CBT approaches (Acceptance and Commitment Therapy, Mindfulness-Based CBT) are effective for GAD

• Mindfulness-based stress reduction (MBSR)
• Applied relaxation training
• Psychodynamic therapy — some evidence suggesting comparable results to CBT in selected patients
• Relaxation training with cognitive components appears more effective than relaxation alone

Maintenance Treatment

• After achieving response, maintain pharmacotherapy for at least 6–12 months to prevent relapse
• Controlled trials show a success rate of ~75–85% with adequate treatment
• Benzodiazepine tapering should be done gradually to avoid withdrawal (rebound anxiety, seizures at high doses)
• A subset of patients may benefit from long-term combined antidepressant + benzodiazepine therapy

Special Populations

Summary Algorithm

GAD Diagnosed
    │
    ├─ Mild–Moderate → CBT ± pharmacotherapy
    │
    ├─ Moderate–Severe → SSRI or SNRI (first-line)
    │       ├─ Add short-term BZD bridge if rapid relief needed
    │       └─ Titrate slowly over 2–6 weeks
    │
    ├─ Partial Response → Augment with buspirone, pregabalin, or quetiapine
    │
    ├─ SSRI/SNRI failure → Switch agent or add CBT
    │
    └─ Treatment-Resistant → Specialist referral; consider TCA, MAOI, combination therapy

Recent Evidence Note: 2024–2025 meta-analyses (PMIDs 40544830, 40367584, 38804215) confirm the established hierarchy but highlight that agomelatine, third-wave CBT, and digital delivery of CBT are increasingly well-supported options. No major paradigm shifts from current first-line recommendations.

GAD Regimen Review: Escitalopram + Clonazepam + Propranolol SR + Donepezil

First — Interpret the Clinical Situation

1. Residual subjective anxiety (psychic — worry, inner tension, inability to "switch off") is inadequately controlled, even if somatic symptoms are suppressed
2. The patient is using cannabis as self-medication for residual anxiety — a well-documented phenomenon in GAD
3. This constitutes comorbid Cannabis Use Disorder (CUD) or at minimum hazardous cannabis use, which must be addressed — "therapy for anxiety disorder using cannabis is limited with the potential harm outweighing the risk" (Rosen's Emergency Medicine)

Analysis of Current Regimen

What to Modify — Step by Step

Step 1: Optimize Escitalopram Dose (Most Important)

• Therapeutic range for GAD: 10–20 mg/day
• Psychic symptoms of anxiety (worry, rumination, inability to "switch off") respond to higher SSRI doses and often require more time to respond than somatic symptoms
• Patients who report needing external calming (cannabis) are showing a clear signal of inadequate psychic anxiolysis — the SSRI is the drug that targets this
• Also ensure adequate duration — at least 4–6 weeks at therapeutic dose before judging response

Step 2: Re-evaluate the Need for Clonazepam

• Long-term clonazepam in a stable GAD patient with "no symptoms" on exam is a maintenance risk
• Benzodiazepines do not treat the psychic/cognitive symptoms of GAD (worry, apprehension)
• Long-term use causes tolerance, dependence, and paradoxically impairs cognitive function — which may itself contribute to the patient seeking cannabis for mental relief
• Do not stop abruptly — taper 10–25% per 1–2 weeks under monitoring
• If the patient becomes symptomatic on taper → escitalopram dose needs further optimization first

Step 3: Stop or Justify Propranolol SR

• Propranolol is not indicated for GAD as monotherapy or long-term maintenance — it only blunts somatic symptoms
• It does not treat the psychic component of GAD at all
• Somatic symptoms should be adequately covered by an optimized SSRI

If the patient has performance anxiety as a discrete component, propranolol 10–40 mg PRN before a triggering event is more rational than SR dosing.

Step 4: Clarify and Review Donepezil

• Donepezil (acetylcholinesterase inhibitor) is used for Alzheimer's disease / dementia — it has no role in standard GAD treatment
• If prescribed for cognitive complaints: recognize that clonazepam itself causes anterograde amnesia and cognitive dulling — this may be creating a drug-on-drug iatrogenic situation (BZD causing cognitive symptoms → donepezil to compensate)
• Consider whether tapering the benzodiazepine might resolve the cognitive concerns making donepezil seem necessary

Step 5: Add CBT / Psychotherapy (Critical)

• Cannabis use as a coping mechanism indicates the patient has no behavioral/cognitive tool for managing intrusive thoughts and residual anxiety
• CBT is the only intervention that directly targets psychic anxiety (worry, rumination) through cognitive restructuring and scheduled worry techniques
• Evidence is clear: CBT + pharmacotherapy > pharmacotherapy alone in GAD
• CBT also directly supports cannabis cessation by providing alternate coping strategies

Step 6: Address Cannabis Use Directly

• Cannabis does not treat anxiety in a sustained way: acute short-term relief is followed by rebound anxiety during abstinence/withdrawal (irritability, anxiety, insomnia)
• This creates a use-withdrawal-anxiety cycle that perpetuates both the cannabis use and the anxiety disorder
• Regular cannabis use in GAD patients has been shown to worsen long-term anxiety outcomes
• Consider structured motivational interviewing toward cessation
• If cannabis use meets CUD criteria (DSM-5: ≥2 of 11 criteria in 12 months), formal CUD treatment (CBT for CUD, contingency management) should be offered

Proposed Modified Regimen

Augmentation Options if Escitalopram Alone is Insufficient After Optimization

• Buspirone (15–60 mg/day in divided doses) — specifically targets psychic anxiety and worry, no abuse potential, no sedation
• Pregabalin (150–600 mg/day) — largest effect size among GAD agents; also treats residual insomnia
• Venlafaxine XR — switch from SSRI to SNRI if no adequate response (norepinephrine component adds benefit for worry/arousal)
• Quetiapine XR (low-dose 50–150 mg/day) — second-line; useful for residual anxiety + insomnia

Summary